Abstract: Provided are cellulose esters useful for inhibiting solution crystallization of drugs. Specific polymers include cellulose esters of formula I: wherein n of the ?-carboxyalkanoyl group, is 3, 4, 6, or 8 to provide a ?-carboxyalkanoyl group chosen from succinoyl, glutaroyl, adipoyl, sebacyl, and suberyl groups; and wherein R is chosen from: a hydrogen atom; and an alkanoyl group chosen from acetyl, propionyl, butyryl, valeroyl, hexanoyl, nonanoyl, decanoyl, lauroyl, palmitoyl, and stearoyl groups; wherein there is a total degree of substitution of the alkanoyl group and the ?-carboxyalkanoyl group of at least 2.0; and wherein the polymer comprises m repeating units where n=1 to 1,000,000, or 10 to 100,000, or 100 to 1,000, such as 1 to 6,000. Embodiments further include compositions comprising cellulose esters and poorly water-soluble drugs, which compositions exhibit greater solubility and stability in solution as compared to the drugs alone.

Abstract: The present invention relates to delivery systems to enhance the bioavailability of flavonoids to improve human health. Flavonoids of interest include but are not limited to curcumin, resveratrol, ellagic acid, naringenin, and quercetin. Flavonoids are important in part because they are known to have beneficial effects on human health, including cardioprotective, antioxidant, and anticancer effects. Utility has been limited by low bioavailability, both in the sense of requiring high doses and in that it has been difficult to carry out proper dose-response studies in the absence of methods to control the actual dose administered. In addition to pharmaceutical applications, there are potential nutraceutical uses, for example in supplements that might be sold in health food stores and pharmacies.